European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
One thousand times more soluble than L-cystine at neutral pH
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Subscribe To Our Newsletter & Stay Updated
